Protalix Biotherapeutics Inc (PLX) FinancialsPLXFinancialProtalix Biotherapeutics Inc

Evaluating the bottom line, Protalix Biotherapeutics Inc maintains a gross margin of -11314.71%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -33702.94%, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively PLX converts its operational activities into shareholder value.

In the context of the broader market, PLX competes directly with industry leaders such as ORMP and IPHA. With a market capitalization of $210.29M, it holds a leading position in the sector. When comparing efficiency, PLX's gross margin of -11314.71% stands against ORMP's N/A and IPHA's 3.59%. Such benchmarking helps identify whether Protalix Biotherapeutics Inc is trading at a premium or discount relative to its financial performance.

Protalix reported a total revenue of $33.8 million in Q1 2026, a remarkable 233.8% year-over-year growth, and a net income of $18.3 million, showcasing a significant improvement in financial health.